MELD评分死亡预测效能及病因潜在作用
该验证研究纳入776例择期TIPS患者和445例非TIPS患者,评估三种MELD版本对3、6、12月死亡的区分度与校准度。结果显示区分度尚可但校准度欠佳,非病毒性肝硬化中更差,建议重新校准并更新模型。
要点
- 三种MELD版本区分度c-statistic为0.66-0.76,但校准度总体不理想。
- 非病毒性肝硬化患者区分度更差,非TIPS队列中恶化更显著。
- MELD-TIPS校准可接受,MELD-Mayo和MELD-UNOS校准差但重校准后改善。
核心结论
- MELD评分总体效能不理想,尤其在非病毒性肝硬化中,建议重新校准并更新模型。
研究设计与样本
- 验证研究纳入776例择期TIPS患者和445例非TIPS患者,评估三种MELD版本的区分度与校准度。
主要发现
- TIPS队列c-statistic为0.66-0.72,非TIPS队列为0.66-0.76。
- 非病毒性肝硬化c-statistic更差,非TIPS队列中恶化更显著。
- MELD-TIPS校准可接受,MELD-Mayo和MELD-UNOS校准 largely unsatisfactory,重校准后改善。
- 年龄、白蛋白和TIPS指征可能用于更新MELD。
临床怎么用
- 临床应用MELD评分时需注意其校准度不足,尤其非病毒性肝硬化患者。
- 可考虑对MELD-Mayo和MELD-UNOS进行重新校准以提高预测准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Although the discriminative ability of the model for end-stage liver disease (MELD) score is generally considered acceptable, its calibration is still unclear. In a validation study, we assessed the discriminative performance and calibration of 3 versions of the model: original MELD-TIPS, used to predict survival after transjugular intrahepatic portosystemic shunt (TIPS); classic MELD-Mayo; and MELD-UNOS, used by the United Network for Organ Sharing (UNOS). We also explored recalibrating and updating the model. METHODS: In total, 776 patients who underwent elective TIPS (TIPS cohort) and 445 unselected patients (non-TIPS cohort) were included. Three, 6 and 12-month mortality predictions were calculated by the 3 MELD versions: discrimination was assessed by c-statistics and calibration by comparing deciles of predicted and observed risks. Cox and Fine and Grey models were used for recalibration and prognostic analyses. RESULTS: In the TIPS/non-TIPS cohorts, the etiology of liver disease was viral in 402/188, alcoholic in 185/130, and non-alcoholic steatohepatitis in 65/33; mean follow-up±SD was 25±9/19±21 months; and the number of deaths at 3-6-12 months was 57-102-142/31-47-99, respectively. C-statistics ranged from 0.66 to 0.72 in TIPS and 0.66 to 0.76 in non-TIPS cohorts across prediction times and scores. A post hoc analysis revealed worse c-statistics in non-viral cirrhosis with more pronounced and significant worsening in the non-TIPS cohort. Calibration was acceptable with MELD-TIPS but largely unsatisfactory with MELD-Mayo and -UNOS whose performance improved much after recalibration. A prognostic analysis showed that age, albumin, and TIPS indication might be used to update the MELD. CONCLUSIONS: In this validation study, the performance of the MELD score was largely unsatisfactory, particularly in non-viral cirrhosis. MELD recalibration and candidate variables for an update to the MELD score are proposed. LAY SUMMARY: While the discriminative performance of the model for end-stage liver disease (MELD) score is credited to be fair to good, its calibration, the correspondence of observed to predicted mortality, is still unsettled. We found that application of 3 different versions of the MELD in 2 independent cirrhosis cohorts yielded largely imprecise mortality predictions particularly in non-viral cirrhosis. Thus, we propose a recalibration and suggest candidate variables for an update to the model.
引用
- D'Amico G, Maruzzelli L, Airoldi A, et al. Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. J Hepatol. 2021. PMID: 34333100. doi:10.1016/j.jhep.2021.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。